AML, Adult Clinical Trials

23 recruiting

Frequently Asked Questions

Common questions about AML, Adult clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 3

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

AML, Adult
Institute of Hematology & Blood Diseases Hospital, China240 enrolled1 locationNCT07132684
Recruiting
Not Applicable

Quality of Life-Guided Transfusion in Refractory MDS or AML

MDSAnemiaAML, Adult
Centre Hospitalier Universitaire de Nice52 enrolled1 locationNCT07328191
Recruiting

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

AML, Adult
French Innovative Leukemia Organisation250 enrolled21 locationsNCT06377579
Recruiting
Phase 1

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

MDSAML, Adult
Stelexis BioSciences125 enrolled13 locationsNCT06533761
Recruiting
Phase 1Phase 2

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

MDSAML, Adult RecurrentALL, Recurrent, Adult
BlueSphere Bio, Inc38 enrolled6 locationsNCT06704152
Recruiting
Not Applicable

MRD-positive AML Clinical Study

AML, Adult
Institute of Hematology & Blood Diseases Hospital, China120 enrolled1 locationNCT07131059
Recruiting

Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia, AdultAML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto397 enrolled2 locationsNCT06513273
Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance

AML, Adult
Abramson Cancer Center at Penn Medicine100 enrolled1 locationNCT05909501
Recruiting
Not Applicable

Venetoclax-Decitabine in Untreated Elderly/Unfit AML

AML, Adult
The Second Hospital of Hebei Medical University39 enrolled1 locationNCT07117422
Recruiting
Phase 1

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDSAML, Adult Recurrent
PureTech90 enrolled9 locationsNCT05829226
Recruiting
Phase 2

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

AML, Adult
ETH Zurich88 enrolled2 locationsNCT06138990
Recruiting
Phase 1

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid LeukemiaAMLLeukemia+2 more
Richard Stone, MD22 enrolled2 locationsNCT06313437
Recruiting

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

AML, Adult
French Innovative Leukemia Organisation1,000 enrolled27 locationsNCT06891144
Recruiting
Phase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation33 enrolled20 locationsNCT06022003
Recruiting
Phase 1

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

AML, Adult
Zhejiang ACEA Pharmaceutical Co. Ltd.84 enrolled1 locationNCT05947344
Recruiting
Phase 1Phase 2

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

Acute Myeloid LeukemiaAMLAML, Adult+1 more
Essen Biotech85 enrolled1 locationNCT06420063
Recruiting

Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

AML, Adult
French Innovative Leukemia Organisation230 enrolled42 locationsNCT06263387
Recruiting

IL-6: A Marker for AML Chemo Sensitivity

AML, Adult
Fujian Medical University Union Hospital72 enrolled1 locationNCT06486350
Recruiting
Phase 1

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

AML, Adult RecurrentNHL, Adult
Shengke Pharmaceuticals (Jiangsu) Limited, China60 enrolled2 locationsNCT05758610
Recruiting
Phase 1

Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

AML, Adult
Zhejiang University24 enrolled1 locationNCT06367673